目的 探讨长链非编码核糖核酸肺腺癌转移相关转录本 1（LncMALAT1）通过竞争性结合微小RNA-506-3p（miR-506-3p）调控Zeste同源物增强子2（EZH2）影响膀胱癌增殖的机制。方法 收集2023年1月—2024年10月的92例外科手术切除的膀胱癌组织及对应的癌旁组织标本, 利用Western blot和定量实时逆转录聚合酶链式反应（qRT-PCR）方法检测LncMALAT1和EZH2的表达情况。根据患者预后分为不良组（n=34）和良好组（n=58）, 收集患者的性别、年龄、肿瘤直径、血管侵袭情况、TNM分期、远处转移情况等临床指标, 结合临床病理指标分析LncMALAT1和EZH2与膀胱癌患者预后的关系。通过体外实验,包括qRT-PCR、Western blot、平板克隆和EdU实验,验证LncMALAT1对EZH2表达和膀胱癌细胞增殖的影响。利用生物信息学技术预测LncMALAT1与miR-506-3p的相互作用,并通过qRT-PCR验证在膀胱癌细胞中上调LncMALAT1表达后miR-506-3p的表达变化。结果 单因素结果显示, 血管侵袭情况、TNM分期、远处转移情况、LncMALAT1及EZH2表达水平均与膀胱癌患者预后不良有关, 差异有统计学意义（均P<0.05）。分析结果发现LncMALAT1与EZH2在膀胱癌组织中的表达呈正相关。体外实验结果显示, 上调LncMALAT1表达后, EZH2的表达显著上调, 且膀胱癌细胞的增殖能力显著提高（均P<0.05）。qRT-PCR验证表明,上调LncMALAT1表达后,miR-506-3p的表达显著下调（P<0.05）, 提示LncMALAT1通过竞争性结合miR-506-3p调控EZH2,进而影响膀胱癌细胞的增殖进展。结论 LncMALAT1通过竞争性结合miR-506-3p调控EZH2促进膀胱癌增殖功能,进而加快膀胱癌细胞的增殖进展, 可为膀胱癌的治疗提供新的潜在靶点。

Objective To explore the mechanism of long non-coding ribonucleic acid metastasis - associated lung adenocarcinoma transcript 1（LncMALAT1）regulating enhancer of Zeste homolog 2（EZH2）through competitive combination with microRNA-506-3p（miR-506-3p）to affect the proliferation of bladder cancer．Methods A total of 92 pairs of bladder cancer tissues and corresponding adjacent normal tissues were collected from surgical resections between January 2023 and October 2024．The expression levels of LncMALAT1 and EZH2 were detected using Western blot and qRT-PCR．The patients were divided into poor group（n=34）and good group（n=58）according to their prognosis．Clinical data, such as gender, age, tumor diameter, vascular invasion, TNM stage, and distant metastasis were collected, and the relationship between LncMALAT1 and EZH2 and the prognosis of bladder cancer patients was analyzed with clinical pathological indicators．Through in vitro experiments, including qRT-PCR Western blot, plate cloning and EdU experiment were conducted to verify the effect of LncMALAT1 on EZH2 expression and bladder cancer cell proliferation．Bioinformatics technology was used to predict the interaction between LncMALAT1 and miR-506-3p, and qRT-PCR was used to verify the change of miR-506-3p expression after up regulating LncMALAT1 expression in bladder cancer cells．Results The univariate results showed that vascular invasion, TNM stage, distant metastasis, LncMALAT1 and EZH2 expression levels were related to the poor prognosis of bladder cancer patients, and the difference was statistically significant（all P<0.05）．The results showed that the expression of LncMALAT1 and EZH2 in bladder cancer was positively correlated．In vitro experiment results showed that after up regulating LncMALAT1 expression, EZH2 expression was significantly up-regulated, and the proliferation ability of bladder cancer cells was significantly improved（all P<0.05）．QRT-PCR validation showed that the expression of miR-506-3p was significantly down regulated after the expression of LncMALAT1 was up-regulated（P<0.05）, suggesting that LncMALAT1 could regulate EZH2 through competitive combination with miR-506-3p, thereby affecting the proliferation and progression of bladder cancer cells．Conclusions LncMALAT1 can promote the proliferation of bladder cancer cells by competitively combining with miR-506-3p to regulate EZH2, and then accelerate the proliferation of bladder cancer cells, which can provide a new potential target for the treatment of bladder cancer．

目的 探讨快速康复外科(enhanced recovery after surgery, ERAS)理念在膀胱癌根治加回肠膀胱术后护理的有效性和安全性。方法 分析我院2012年1月—2016年12月行膀胱癌根治加回肠膀胱术的患者共98例,其中ERAS组47例,传统组51例。比较两组术后伤口感染率、出血率、吻合口瘘率、肺部感染率及术后住院日等指标。结果 两组患者的伤口感染率、出血率、吻合口瘘率无差异,ERAS组的肺部感染率4.26%低于传统组21.57%,差异有统计学意义(P＜0.05)。ERAS组的术后住院日短于对照组[(8.53±1.82)vs (13.21±2.16)],差异有统计学意义(P＜0.05)。ERAS组的30天内再入院率6.38%低于传统组19.61%,差异有统计学意义(P＜0.05)。两组的非计划再次手术率无统计学差异。结论 快速康复外科理念应用在膀胱癌根治加回肠膀胱术后护理是有效和安全的,ERAS能减少术后并发症及缩短术后住院日。

       目的   探讨预防性风险管理在肌层浸润性膀胱癌根治术后的应用效果及对术后生活质量影响。方法   选取2020年6月—2023年10月安阳市肿瘤医院收治的66例肌层浸润性膀胱癌患者，应用抽签法分为观察组（n=33）与对照组（n=33）。所有患者均采取根治性全膀胱切除术与淋巴清扫术治疗，对照组患者术后实施常规护理，观察组在对照组基础上增加预防性风险管理。对比两组术后尿量、胃肠功能恢复时间、术后住院时间，干预前后病耻感及负面情绪、术后并发症发生率，最后对比两组干预前后生活质量变化。结果   两组患者术后尿量对比差异无统计学意义（P＞0.05），观察组术后胃肠功能恢复时间为（5.27±0.82）d，术后住院时间为（18.31±3.27）d，短于对照组的（7.25±1.12）（23.27±4.18）d，对比差异有统计学意义（t分别为8.194、5.369，P＜0.05）；干预后两组患者病耻感量表（SSCI）、抑郁自评量表（SDS）和焦虑自评量表（SAS）评分均降低，观察组分别为（35.67±7.45）（40.02±2.43）（45.36±4.17）分，低于对照组的（48.27±10.69）（54.54±3.54）（51.37±4.38）分，对比差异有统计学意义（t分别为5.555、19.426、5.709，P＜0.05）；观察组术后并发症发生率为9.09%，低于对照组的30.30%（χ ² =4.690，P=0.030）；干预后两组膀胱癌特异性模块、功能状况、精神状况、家庭/社会状况及躯体状况相关维度膀胱癌患者生活质量量表（FACT-BL）评分均升高，观察组分别为（34.27±3.26）（25.11±4.23）（21.51±4.23）（25.02±4.43）（20.56±3.11）分，高于对照组的（27.00±4.34）（21.11±3.24）（16.12±2.12）（21.54±5.54）（15.87±4.13）分，对比差异有统计学意义（t分别为7.694、4.313、6.544、2.818、5.211，P＜0.05）。结论   预防性风险管理在肌层浸润性膀胱癌根治术后的应用效果显著，可缩短患者术后胃肠功能恢复时间及住院时间，改善患者负面情绪，有助减少术后并发症，提升患者生活质量。

       Objective  To explore the effect of preventive risk management on postoperative application and quality of life of myometrial invasive bladder cancer patients after radical surgery．Methods  A total of 66 patients with myometrial invasive bladder cancer admitted to Anyang Cancer Hospital from June 2020 to October 2023 were selected as research objects，and were divided into observation group（n=33）and control group（n=33）by lot drawing．All patients were treated with  radical total cystectomy and lymph node dissection．The control group received routine nursing care after surgery，while the observation group received preventive risk management in addition to the control group．The postoperative urine output，recovery time of gastrointestinal function，and hospitalization time between two groups were compared，as well as the shame and negative emotions before and after intervention，the incidence of postoperative complications，and the changes in quality of life between the two groups before and after intervention．Results  There was no significant difference in postoperative urine volume between the two groups of patients（P＞0.05），and the postoperative gastrointestinal function recovery time（5.27±0.82）d，postoperative hospitalization time（18.31±3.27）d were shorter than the control group［（7.25±1.12）d，（23.27±4.18）d］，with statistical significantce（t=8.194，5.369，P＜0.05）．After intervention，the Stigma Scale of Chronic Illness（SSCI），Self Rating Depression Scale（SDS），and Self-Rating Anxiety Scale（SAS）in both groups of patients decreased，and the observation group［（35.67±7.45），（40.02±2.43），（45.36±4.17）］scored lower than the control group［（48.27±10.69），（54.54±3.54），（51.37±4.38）］，statistically significant（t=5.555，19.426，5.709，P＜0.05）．The incidence of postoperative complications in the observation group was significantly lower at 9.09% compared to the control group at 30.30%（χ ² =4.690，P=0.030，P＜0.05）．After intervention，the scores of bladder cancer specific module，functional status，mental status，family/social status and physical status  related dimensions of bladder cancer patients’ quality of life scale for bladder cancer patients（FACT-BL）in both groups increased，and the observation group［（34.27±3.26），（25.11±4.23），（21.51±4.23），（25.02±4.43），（20.56±3.11）］ scored higher than the control group［（27.00±4.34），（21.11±3.24），（16.12±2.12），（21.54±5.54），（15.87±4.13）］，the comparison was statistically significant（t=7.694，4.313，6.544，2.818，5.211，P＜0.05）．Conclusions  Preventive  risk management has a significant effect on the application of myometrial invasive bladder cancer after radical surgery，which can shorten the recovery time of gastrointestinal function and hospital stay，improve patients’ negative emotions，assist in preventing postoperative complications，and improve patients’ quality of life．

       目的   探讨非肌层浸润性膀胱癌患者初次经尿道膀胱肿瘤电切术的复发情况及危险因素。方法   以93例非肌层浸润性膀胱癌患者进行研究，2018年1月至2022年1月西藏自治区人民政府驻成都办事处医院泌尿外科医院收治采取经尿道膀胱肿瘤电切术，术后随访24个月，复发22例，未复发71例，比较复发与未复发基础情况、不同肿瘤直径、不同肿瘤分期、分级、数量、是否带蒂、灌注化疗方式等特征患者的复发情况，对具有统计学意义的因素，采取非条件Logistic多因素回归分析，明确术后复发的危险因素。结果   肿瘤分期T1期者的复发率为32.08%，高于Ta期者15.50%，肿瘤分级为高级别者的复发率为53.33%，高于低级别者17.95%，肿瘤多发者的复发率为35.71%，高于单发者的13.73%，肿瘤不带蒂者的复发率为38.71%，高于肿瘤带蒂者的16.13%，常规灌注化疗患者的复发率为29.85%，高于术后即刻+灌注化疗患者的7.69%，比较差异均有统计学意义（χ ² 分别为6.648、4.836、6.872、6.166、5.834、5.902，P分别为0.010、0.027、0.008、0.013、0.015、0.024）。肿瘤分期T1期、肿瘤分级为高级别、肿瘤多发、常规灌注化疗为非肌层浸润性膀胱癌行初次经尿道膀胱肿瘤电切术的术后复发的危险因素（P＜0.05）。结论   非肌层浸润性膀胱癌患者初次采取经尿道膀胱肿瘤电切术容易因为临床分期为T1期、肿瘤分级为高级别、肿瘤多发及常规灌注等出现复发，应采取针对性干预措施，改进灌注化疗方式，降低复发率。

       Objective  To investigate the  relapse and  risk factors of non-muscular invasive bladder cancer after primary transurethral resection．Methods  A total of 93 patients with non-muscular invasive bladder cancer were selected for study．They were received by the hospital from January 2018 to January 2022 and underwent transurethral resection．After 24 months of follow-up，22 patients recurred，and 71 patients did not recur．The recurrence of patients with different tumor diameter，tumor stage，grade，numbers，pedicel or not，and infusion chemotherapy methods were compared．For the statistically significant factors，unconditional logistic regression analysis was used to determine the independent risk factors for recurrence．Results  The recurrence rate in T1 stage of tumor was 32.08% higher than that in Ta stage，which was 15.50%．The recurrence rate in high stage was 53.33% higher than that in low stage，which was 17.95%．The recurrence rate in multiple tumor patients was 35.71% higher than that in single tumor patients，which was 13.73%．The no-pedicle tumor recurrence rate was 38.71% higher than that with pedicle，which was 16.13%．The recurrence rate in patients receiving conventional infusion chemotherapy was 29.85% higher than that in patients receiving immediate postoperative infusion chemotherapy，which was 7.69%．The differences were statistically significant（χ ² =6.648、4.836、6.872、6.166、5.834、5.902，P=0.010、0.027、0.008、0.013、0.015、0.024）．The independent  risk factors of recurrence after primary transurethral resection were tumor stage T1，high grade tumors，multiple tumors，routine perfusion chemotherapy as non-muscular invasive bladder cancer（P＜0.05）．Conclusions  The  patients with  non-muscular invasive bladder cancer taking transurethral resection for the first time are prone to recurrence because of the clinical stage of T1，tumor grade of high grade，multiple tumors and routine perfusion．Targeted intervention measures  should be taken to improve the perfusion chemotherapy method to reduce the recurrence rate．